RxDoctor Payments Data

Charlene Andrews, MD

Internal Medicine · Jamaica, NYNPI 1982647129

Payments from drug & device makers

$3,951in general payments, 2019–2025

Across 191 payments — averaging $20.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • Lilly USA, LLC$657
  • AstraZeneca$616
  • Mannkind Corporation$228
  • AbbVie$188
  • Bayer$164
  • plus $745 from 14 others

What the payments were for

  • Food & beverage$3,83297%
  • Gifts$1193%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,951 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$164,544
Medicare patients
171
Services billed
2,295

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide81$94,272
MounjaroTirzepatide44$50,677
JanuviaSitagliptin Phosphate38$28,758
JardianceEmpagliflozin23$20,671
LinzessLinaclotide20$19,746
EliquisApixaban13$14,856
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog19$8,181
FarxigaDapagliflozin Propanediol12$6,735
Lantus SolostarInsulin Glargine,hum.Rec.Anlog29$2,978
Clonidine24$2,348
Albuterol Sulfate HfaAlbuterol Sulfate49$2,279
Rosuvastatin Calcium86$1,375
Diclofenac Sodium35$1,329
Atorvastatin Calcium170$1,293
Amlodipine Besylate230$1,212

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,353$94,27281 claims
Lilly USA, LLCMounjaro$657$50,67744 claims
Boehringer IngelheimJardiance$80$20,67123 claims
AbbVieLinzess, Synthroid$188$20,54339 claims
PfizerEliquis$20$14,85613 claims
AstraZenecaFarxiga$616$6,73512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Jamaica

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →